SIBO: Diagnosis, Treatment, and Microbiome Restoration

Small intestinal bacterial overgrowth (SIBO) is defined as an abnormal increase in the number or type of bacteria in the small intestine, typically exceeding 10⁵ colony-forming units per milliliter of jejunal aspirate, or producing abnormal hydrogen/methane on breath testing. SIBO is more prevalent than commonly appreciated — studies suggest it underlies 30-80% of IBS cases, and it is frequent in conditions affecting gut motility, anatomy, and immune defense.

Pathophysiology

The small intestine is normally kept relatively sterile (10³-10⁴ CFU/mL) through migrating motor complex activity, secretory IgA, bile acids, and ileocecal valve competence. Disruption of any of these mechanisms permits ascending colonization from the colon. Common predisposing conditions: gastroparesis, post-surgical anatomy (Roux-en-Y, ileocecal resection), celiac disease, hypothyroidism, and chronic PPI use — which reduces gastric acid-mediated bacterial clearance.

Diagnosis

Lactulose and glucose breath testing remain the most accessible diagnostic tools, though jejunal aspirate culture is the gold standard. The North American Consensus criteria (Rezaie et al., Am J Gastroenterol, 2017) provide updated diagnostic thresholds. Hydrogen-dominant SIBO typically indicates fermentative species overgrowth; methane-dominant SIBO (intestinal methanogen overgrowth, IMO) is associated with constipation-predominant IBS and is driven by archaea rather than bacteria.

Treatment and Microbiome Impact

Rifaximin (1650mg/day × 14 days) achieves 50-70% eradication in hydrogen SIBO with minimal systemic absorption. For methane-dominant SIBO, rifaximin plus neomycin or lovastatin combinations show superior efficacy. However, antibiotic treatment alone does not address the predisposing dysbiosis. Post-treatment microbiome restoration is essential — see our articles on antibiotic stewardship and evidence-based probiotic use.

Prokinetics and Relapse Prevention

SIBO recurrence rates without addressing underlying motility are high (>40% at 9 months). Low-dose naltrexone (LDN), prucalopride, and elemental diets between treatment cycles support migrating motor complex restoration. Elimination of PPI if clinically feasible is a high-yield intervention.

See also: IBS and the Microbiome · Leaky Gut Syndrome